Compare
Bioharvest Sciences Inc. vs Verrica Pharmaceuticals Inc. vs Earth Science Tech, Inc. vs Sunshine Biopharma Inc.
| Latest fiscal year | Bioharvest Sciences Inc. BHST | Verrica Pharmaceuticals Inc. VRCA | Earth Science Tech, Inc. ETST | Sunshine Biopharma Inc. SBFM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | $34.51M | $35.58M | $35.70M | $36.31M |
| Revenue growth (YoY) | +37.0% | +370.2% | +7.8% | +4.1% |
| Gross margin | 59.3% (computed) | n/a | 71.4% | 33.8% |
| Operating margin | -16.2% | -34.2% | n/a | -17.2% |
| Net margin | -32.3% | -50.3% | 10.2% | -16.5% |
| Net income | -$11.13M | -$17.89M | $3.63M | -$5.98M |
| EPS (Diluted) | n/a | -$1.68 | $0.012 | n/a |
| Operating cash flow | -$7.23M | -$17.63M | $1.94M | -$5.33M |
| Free cash flow | -$9.58M | -$17.63M | $1.18M | -$5.51M |
| Cash & equivalents | $23.02M | $30.15M | $796.8K | n/a |
| Total assets | n/a | $47.13M | $8.97M | $30.08M |
| Total liabilities | n/a | $22.39M | $1.93M | $7.04M |
| Shareholders' equity | $25.45M | $24.74M | $7.01M | $23.04M |
| Return on year-end equity | -43.8% | -72.3% | 51.8% | -25.9% |
| Shares outstanding | n/a | 17.18M | 291.32M | 4.91M |
Revenue, most recent five fiscal years
| Fiscal year | Bioharvest Sciences Inc. | Verrica Pharmaceuticals Inc. | Earth Science Tech, Inc. | Sunshine Biopharma Inc. |
|---|---|---|---|---|
| Latest | $34.51M Ended 2025-12-31 | $35.58M Ended 2025-12-31 | $35.70M Ended 2026-03-31 | $36.31M Ended 2025-12-31 |
| 1 year earlier | $25.19M Ended 2024-12-31 | $7.57M Ended 2024-12-31 | $33.12M Ended 2025-03-31 | $34.87M Ended 2024-12-31 |
| 2 years earlier | $12.67M Ended 2023-12-31 | $5.12M Ended 2023-12-31 | $11.95M Ended 2024-03-31 | $24.09M Ended 2023-12-31 |
| 3 years earlier | n/a | $9.03M Ended 2022-12-31 | $48.5K Ended 2023-03-31 | $4.35M Ended 2022-12-31 |
| 4 years earlier | n/a | $12.00M Ended 2021-12-31 | $14.1K Ended 2022-03-31 | $228.4K Ended 2021-12-31 |